(HealthDay)—There are considerable gaps in knowledge relating to the effectiveness of non-pharmacologic treatments for attention-deficit/hyperactivity disorder (ADHD) in pediatric patients, according to a review published ...
Jun 2, 2018
0
5
The drug combination sofosbuvir/velpatasvir (trade name: Epclusa) has been approved since July 2016 for the treatment of patients with chronic hepatitis C (CHC). In an early benefit assessment, the German Institute for Quality ...
Oct 17, 2016
0
1
Sleep disturbances are a frequent complaint of women in the menopause transition and postmenopause. A new study demonstrates that women with premature ovarian insufficiency (POI) who are receiving hormone therapy have poorer ...
Jul 16, 2019
0
10
Dabrafenib (trade name: Tafinlar) has been approved since 2013 for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. Since September 2015, dabrafenib has been approved ...
Jan 13, 2016
0
0
An increasing number of new anti-cancer drugs are approved each year. During the authorization process, such new drugs usually undergo comparisons to other single drugs, but only rarely to multiple established drugs. This ...
Feb 14, 2019
0
0
In an analysis of three different types of radiation therapy used to treat localized prostate cancer, compared with conformal radiation therapy, intensity-modulated radiation therapy (IMRT) was associated with fewer diagnoses ...
Apr 17, 2012
0
1
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. ...
Aug 18, 2016
0
1
The fixed-dose combination of the drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide has been available under the trade name Genvoya since November 2015 as treatment for adults and adolescents aged over ...
Apr 6, 2016
0
4
Internet-based cognitive behavioral therapy (CBT) for depression is often just as effective as traditional CBT. This is clear from an international study involving scientists at the University of Gothenburg. However, some ...
Aug 2, 2021
0
70
Ospemifene (tradename: Senshio) is approved for the treatment of moderate to severe symptomatic vulvovaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy. The drug has ...
Aug 10, 2016
0
0
